Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a selective 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a 5‑HT3 antagonist used in the management of nausea and vomiting associated with chemotherapy and related triggers. - Chemotherapy‑induced nausea and vomiting (CINV): Provides effective prophylaxis before the start of highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Reduces the incidence of nausea and vomiting after surgical procedures requiring anesthesia. - Radiotherapy‑induced nausea and vomiting: Helps control nausea associated with radiation treatment of the abdomen or pelvis. - Anticipated future future future future future future future future ...

Palonosetron, like other 5‑HT3 antagonists, may cause a range of adverse reactions.

Common Side Effects: - Headache  - Constipation  - Fatigue  - Diarrhea  - Dizziness

Serious or Rare Side Effects: - QT‑interval prolongation - Severe hypersensitivity reactions (anaphylaxis, angio‑angelf ) - Serotonin syndrome  - Cardiac arrhythmia  - Pulmonary edema 

When using Palonosetron Fresenius Kabi, clinicians should consider several safety aspects. - Cardiac monitoring: Assess  g  g  g  ewline -   g  ewline   ewline   ewline ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...  -  ",